CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study to determine the maximum tolerated dose of CP-870,893

Trial Profile

CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study to determine the maximum tolerated dose of CP-870,893

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs CP 870893 (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Sep 2015 Status changed from active, no longer recruiting to completed according to the results in the Annals of Oncology.
    • 18 Sep 2015 Results published in the Annals of Oncology.
    • 18 Oct 2011 Status changed from not yet recruiting to active, no longer recruiting according to Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top